Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction

Japanese Circulation Journal

Volumn 64, Issue 8, 2000, Pages 547-553

  Soeki, T ^a   Tamura, Y ^a   Fukuda, N ^a   Ito, S ^a  

^a National Hospital Organization   (Japan)

Author keywords

Acute myocardial infarction; Plasminogen activator inhibitor 1; Platelet

Indexed keywords

ALPHA 2 ANTIPLASMIN; BETA THROMBOGLOBULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; THROMBOCYTE; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0033850676     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.64.547     Document Type: Article

References (37)

1. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death
2. Immuno-chemical characterization of fibrinogen, fibrin I and fibrin II in human thrombi and atherosclerotic lesions
3. Thrombosis and the development of atherosclerosis: Rokitansky revisited
4. Atherosclerosis and the coagulation system
5. Plasminogen activator inhibitors
6. Type 1 plasminogen activator inhibitor
7. The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease
8. Haemostasis factors in angina pectoris: Relation to gender, age and acute-phase reaction: Results of the ECAT Angina Pectoris Study Group
9. Plasminogen activator inhibitor type 1 determines plasmin formation in patients with ischaemic heart disease
10. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells
11. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease
12. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
13. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction
14. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI)
15. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications
16. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction
17. Plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina
18. Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction
19. Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction
20. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease
21. Platelet release protein which inhibits plasminogen activators
22. Plasminogen activator inhibitor (PAI-1) in plasma and platelets
23. Studies on the liberation of β-thromboglobulin from human platelets in vitro
24. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes
25. Plasminogen activator inhibitor in the blood of patients with coronary artery disease
26. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
27. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture
28. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets
29. Studies on the release of a plasminogen activator inhibitor by human platelets
30. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets
31. Studies of recombinant plasminogen activator inhibitor-1 in rabbits: Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor 1 in vivo
32. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288
33. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization
34. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood
35. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
36. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men
37. Serial changes of plasminogen activator inhibitor activity in acute myocardial infarction: Difference between thrombolytic therapy and direct coronary angioplasty